Document:

Voting Agreement

 Exhibit 10.14 
 CAI INTERNATIONAL, INC. 
 VOTING AGREEMENT 
 February 16, 2007 

 TABLE OF CONTENTS 
  

					
	 1.
	  	Election of Directors.	  	1
		  	1.1    Board Representation.	  	1
		  	1.2    Appointment of Directors.	  	2
			
	 2.
	  	Additional Representations and Covenants.	  	2
		  	2.1    No Revocation.	  	2
		  	2.2    Legends.	  	2
		  	2.3    Covenants of the Parties.	  	2
		  	2.4    No Liability for Election of Recommended Directors.	  	3
		  	2.5    Grant of Proxy.	  	3
		  	2.6    Specific Enforcement.	  	3
		  	2.7    Execution by the Company.	  	3
			
	 3.
	  	Termination.	  	3
		  	3.1    Termination Events.	  	3
		  	3.2    Removal of Legend.	  	3
			
	 4.
	  	Miscellaneous.	  	4
		  	4.1    Successors and Assigns.	  	4
		  	4.2    Amendments and Waivers.	  	4
		  	4.3    Notices.	  	4
		  	4.4    Severability.	  	4
		  	4.5    Governing Law.	  	4
		  	4.6    Counterparts.	  	5
		  	4.7    Titles and Subtitles.	  	5
		  	4.8    Manner of Voting.	  	5
		  	4.9    Stock Splits, Stock Dividends, etc.	  	5
		  	4.10  Binding Effect.	  	5

 CAI INTERNATIONAL, INC. 
 VOTING AGREEMENT 
 This Voting Agreement
(this “Agreement”) is made as of February 16, 2007, by and among Hiromitsu Ogawa (“Seller”), DBJ Value Up Fund, a Japanese partnership (“DBJ”) and CAI International
Inc., a Delaware corporation (the “Company”). The Company was formerly known as “Container Applications International, Inc.,” and changed its name to “CAI International, Inc.” on February 2, 2007, at
the time it reincorporated in the State of Delaware. 
 RECITALS 
 WHEREAS, Seller, DBJ and the Company intend to execute a Stock Purchase Agreement of even date herewith (the “Purchase
Agreement”), pursuant to which DBJ intends to purchase and Seller intends to sell 4,028 shares of the Company’s Common Stock (the “Shares”); 
 WHEREAS, the execution of this Agreement on or by the Closing (as defined in the Purchase Agreement) is a condition of the Seller’s and DBJ’s
mutual obligations at the Closing under the Purchase Agreement; 
 WHEREAS, in order to induce Seller and the Company to approve the sale of
the Shares and to induce DBJ to purchase the Shares pursuant to the Purchase Agreement, Seller, DBJ and the Company hereby agree that this Agreement shall set forth the terms and conditions pursuant to which Seller and DBJ shall vote their shares of
the Company’s voting stock in favor of certain designees to the Company’s Board of Directors; and 
 WHEREAS, Seller, DBJ and the
Company each desire to facilitate the voting arrangements set forth in this Agreement, and the sale and purchase of the Shares pursuant to the Purchase Agreement, by agreeing to the terms and conditions set forth below; 
 AGREEMENT 
 NOW, THEREFORE, in
consideration of the premises and the mutual covenants herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 
 1. Election of Directors. 
 1.1
Board Representation. If the Company has not completed an initial public offering of its common stock (“IPO”) within the period ending the first anniversary of execution of this Agreement, DBJ shall be entitled
to appoint a director to the Company’s Board of Directors, as provided in this Agreement. Commencing on the first anniversary of 

 
this Agreement, and provided that the Company’s IPO has not been completed, at each annual meeting of the shareholders of the Company, or at any meeting
of the shareholders of the Company at which members of the Board of Directors of the Company are to be elected, or whenever members of the Board of Directors are to be elected by written consent, Seller and DBJ agree on behalf of themselves and any
transferee or assignee of the Shares, to vote or act with respect to all of such Shares and any other securities of the Company acquired by Seller or DBJ in the future (and any securities of the Company issued with respect to, or in exchange or
substitution for such securities) (the “Common Holder Shares”) so as to elect one (1) representative of DBJ (the “DBJ Designee”) to the Company’s Board of Directors in accordance with Article
V of the Company’s Certificate of Incorporation (the “Charter”). Aside from the DBJ Designee, Seller and DBJ shall be entitled to vote for the other members of the Board of Directors of the Company freely and without
being bound by this Agreement. 
 1.2 Appointment of Directors. All directors designated and elected under this Agreement shall
be entitled to indemnification by the Company, as may be set forth in the Charter, the Company’s Bylaws and in the Company’s standard form indemnification agreement. All directors shall further be entitled to benefit from any D&O
insurance policy that may be adopted by the Company after the Closing. In the event of the resignation, death, removal or disqualification of the DBJ Designee, Seller and DBJ voting as single class shall promptly designate and elect a new director
as the DBJ Designee, and Seller and DBJ shall vote their shares of capital stock of the Company as set forth in Section 1.1. 
 2.
Additional Representations and Covenants. 
 2.1 No Revocation. The voting agreements contained herein are coupled
with an interest and may not be revoked during the term of this Agreement. 
 2.2 Legends. Each certificate representing shares
of the Company’s capital stock held by the DBJ or any assignee thereof shall bear the following legend: 
 “THE SECURITIES EVIDENCED
BY THIS CERTIFICATE ARE SUBJECT TO A VOTING AGREEMENT BY AND AMONG THE CORPORATION AND CERTAIN SHAREHOLDERS OF THE CORPORATION (A COPY OF WHICH MAY BE OBTAINED FROM THE CORPORATION), AND BY ACCEPTING ANY INTEREST IN SUCH SHARES THE PERSON ACCEPTING
SUCH INTEREST SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL THE PROVISIONS OF SAID VOTING AGREEMENT.” 
 2.3 Covenants
of the Parties. The parties hereto agree to use their respective commercially reasonable best efforts to ensure that the rights granted hereunder are effective and that the parties hereto enjoy the benefits thereof. Such actions include,
without limitation, the use of the parties’ commercially reasonable best efforts to cause the designation and election of the directors as provided above. The parties will not, by any 

 
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be performed hereunder by the parties, but will at all times in
good faith assist in the carrying out of all of the provisions of this Agreement and in the taking of all such actions as may be necessary or appropriate. 
 2.4 No Liability for Election of Recommended Directors. Neither Seller, DBJ, the Company, nor any officer, director, shareholder, partner, employee or agent of such party, makes any representation or
warranty as to the fitness or competence of the DBJ Designee to serve on the Company’s Board of Directors by virtue of such party’s execution of this Agreement or by the act of such party in designating or voting in favor of such designee
pursuant to this Agreement. 
 2.5 Grant of Proxy. Upon the failure of Seller or DBJ to vote their Shares in accordance with
the terms of this Agreement, Seller or DBJ hereby grants to a shareholder designated by the Board of Directors of the Company a proxy coupled with an interest in all Common Holder Shares owned by Seller or DBJ (which proxy shall be irrevocable until
this Agreement terminates pursuant to its terms, or this Section 2.5 is amended to remove such grant of proxy in accordance with Section 4.2 hereof) to vote all such Common Holder Shares in the manner provided herein. 
 2.6 Specific Enforcement. It is agreed and understood that monetary damages would not adequately compensate an injured party for the breach
of this Agreement by any party, that this Agreement shall be specifically enforceable, and that any breach or threatened breach of this Agreement shall be the proper subject of a temporary or permanent injunction or restraining order. Further, each
party hereto waives any claim or defense that there is an adequate remedy at law for such breach or threatened breach. 
 2.7 Execution
by the Company. The Company, by its execution in the space provided below, further agrees that it will cause the certificates issued after the date hereof evidencing the Common Holder Shares to bear the legend required by Section 2.2
hereof, and it shall supply, free of charge, a copy of this Agreement to any holder of a certificate evidencing Common Holder Shares upon written request from such holder to the Company at its principal office. The parties hereto do hereby agree
that the failure to cause the certificates evidencing the Common Holder Shares to bear the legend required by Section 2.2 hereof and/or failure of the Company to supply, free of charge, a copy of this Agreement, as provided under this
Section 2.7, shall not affect the validity or enforcement of this Agreement. 
 3. Termination. 
 3.1 Termination Events. This Agreement shall terminate at such time as (i) the Company consummates the IPO (whether before or after the
one-year anniversary of this Agreement); (ii) DBJ ceases to own at least two-thirds (2/3) of the Shares or (iii) Seller, DBJ and the Company consent to terminate this Agreement subject to Section 4.2. 

 3.2 Removal of Legend. At any time after the termination of this Agreement in accordance
with Section 3.1, any holder of a stock certificate legended pursuant to Section 2.2 may surrender such certificate to the Company for removal of the legend, and the Company will duly reissue a new certificate without the legend.

 4. Miscellaneous. 
 4.1 Successors and Assigns. DBJ’s rights under this Agreement are personal rights to DBJ, that may not be assigned. Except as otherwise provided herein (including the foregoing sentence), the terms and conditions of this
Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties hereto (including transferees of any shares held by either Seller or DBJ). Nothing in this Agreement, express or implied, is intended to
confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 4.2 Amendments and Waivers. This Agreement and the documents referred to herein constitute the full and entire understanding and agreement
among the parties hereto with regard to the subjects hereof and thereof, and no party shall be liable or bound to any other party in any manner by any warranties, representations, or covenants, except as specifically set forth herein or therein. Any
term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of (i) Seller,
(ii) DBJ and (iii) the Company. Any amendment or waiver so effected shall be binding upon all the parties hereto, including each of their respective successors and assigns. 
 4.3 Notices. Unless otherwise provided, any notice under this Agreement shall be given in writing and shall be deemed effectively delivered
(a) upon personal delivery to the party to be notified, (b) upon confirmation of receipt by facsimile by the party to be notified, (c) one (1) business day after deposit with a reputable overnight courier, prepaid for overnight
delivery and addressed as set forth in (d), or (d) three days after deposit with the United States Postal Service, postage prepaid, registered or certified with return receipt requested and addressed to the party to be notified at the address
indicated for such party on the exhibits hereto, or at such other address as such party may designate by written notice to the other party given in the foregoing manner. 
 4.4 Severability. If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement
shall be interpreted as if such provision or provisions were so excluded and shall be enforceable in accordance with its terms. Each party agrees to promptly notify the other party at such time that it becomes aware of any terms of this Agreement
that are not enforceable. 

 4.5 Governing Law. This Agreement and all acts and transactions pursuant hereto and the
rights and obligations of the parties hereto shall be governed by and construed under the laws of the State of New York, without giving effect to principles of conflicts of law thereof. The parties consent to the exclusive jurisdiction of and venue
in the state courts in New York City in the State of New York (or in the event of exclusive federal jurisdiction, the courts of the Southern District of New York). 
 4.6 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. 

4.7 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 4.8 Manner of Voting. The voting of shares pursuant to this Agreement may be
effected in person, by proxy, by written consent, or in any other manner permitted by the Company’s Bylaws and applicable law. 
 4.9
Stock Splits, Stock Dividends, etc. In the event of any issuance of shares of the Company’s voting securities hereafter to any of the parties hereto (including, without limitation, in connection with any stock split, stock
dividend, recapitalization, reorganization, or the like), such shares shall become subject to this Agreement and shall be endorsed with the legend set forth in Section 2.2. 
 4.10 Binding Effect. In addition to any restriction that may be imposed by any other agreement by which any party hereto may be bound, this
Agreement shall be binding upon the parties, their respective heirs, successors and assigns and to such additional individuals or entities that may become shareholders of the Company and that desire to become parties hereto. Upon the transfer to a
transferee reasonably acceptable to the Company, such transferee shall be deemed to be a party hereto as if such transferee’s signature appeared on the signature pages hereto. 
 [SIGNATURE PAGES FOLLOW] 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.

  

			
	“SELLER”
	
	 /s/ Hiromitsu Ogawa

	Hiromitsu Ogawa

  

			
	“DBJ”
	
	 DBJ VALUE UP FUND
 a Japanese
partnership

		
	By:	 	 /s/ Masaski Kumagne

	Name:	 	Masaski Kumagne
	Title:	 	President
	
	“COMPANY”
	
	 CAI INTERNATIONAL, INC.
 a Delaware
corporation

		
	By:	 	 /s/ Masaaki Nishibori

	Name:	 	Masaaki Nishibori
	Title:	 	Chief Executive OfficerTerms Sheet

 Exhibit 10.1 
 TERMS SHEET 
 COMMONWEALTH BIOTECHNOLOGIES INC 
 AND 
 TRIPOS INC 
 April 18, 2007 

 This Terms Sheet, dated April 18, 2007 is entered into between 
 COMMONWEALTH BIOTECHNOLOGIES INC of 601 Biotech Drive, Richmond, VA 23235 USA (“CBI”); 
 and 
 TRIPOS INC of 1699 South Hanley Road, St. Louis, MO 63144-2319
USA (“TRIPOS”). 
 Introduction 
 A. CBI
is a NASDAQ Capital Market listed company (NASDAQ Capital Market Code “CBTE”) that specializes in life sciences R&D outsourcing and offers cutting-edge expertise and a complete array of the most current synthetic and analytical
technologies for the life science and bio-defence industries. 
 B. TRIPOS is a NASDAQ General Market listed company (NASDAQ General Market Code
“TRPS”) that combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. 
 C. TRIPOS is the legal and sole beneficial owner of all outstanding equity securities of Tripos Discovery Research [Pte Ltd] (“TDR”), which is a highly
specialised medicinal and synthetic chemistry development company. 
 D. This Terms Sheet is intended to summarise the principal terms of CBI’s proposed
acquisition of TDR from Tripos. 

	1.	PROPOSED ACQUISITION 

 CBI will acquire 100% of the
outstanding equity securities of TDR (the “Transaction”). 
  

	2.	CONSIDERATION 

 Subject to the satisfaction of the
conditions precedent noted below, CBI will acquire TDR for US$500,000 payable in cash (the “Transaction”). As a result of the Transaction, CBI will become the legal and beneficial owner of TDR, except for Receivables of US$1,800,000 (the
“Base Receivables”), a sum that reflects US$720,559 of cash Advances to TDR that has been used as operating capital to cover employee salaries, business creditors, and capital lease payments. In the event that Tripos, in its discretion,
makes further cash advances prior to completion of the transaction, the Base Receivables will be increased dollar for dollar in respect of the additional amounts Advanced up to the maximum value of the Receivables on completion of the Transaction.
Tripos will collect outstanding and billed Receivables and retain those amounts up to the Base Receivables, as increased. Sums above this Base Receivable amount will be remitted to TDR. 
  

	3.	EMPLOYMENT ARRANGEMENTS 

 Contemporaneously with the
execution of definitive agreements for the Transaction, certain key men will be identified who must enter into a mutually acceptable employment agreements to become effective as of the closing of the Transaction. 
  

	4.	REPRESENTATIONS AND WARRANTIES 

 In the documents
effecting the Transaction, the parties will make customary representations and warranties (which will survive the closing of the Transaction) relating to the business, financial condition, contracts, liabilities, employees, and prospects of the
parties and will provide customary indemnities. The Transaction documents will also contain customary covenants, closing conditions, and other provisions. 
  

	5.	CONDITIONS PRECEDENT 

 The following are conditions precedent to the
completion of the Transaction: 
  

	 	•	 	 The Board of Tripos approves the Transaction; 

  

	 	•	 	 The Board of CBI approves the Transaction; 

  

	 	•	 	 All necessary regulatory approvals are obtained both in the United Kingdom and in the United States of America; 

  

	 	•	 	 Completion of a satisfactory due diligence exercise by CBI into the affairs of TDR and the Board of CBI shall have considered the results of the due diligence
exercise and be satisfied with the outcome, in their sole and absolute discretion; 

  

	 	•	 	 The following prescribed events do not occur prior to or during the period from the signing of this Terms Sheet and the completion of the Transaction:

  

	 	•	 	 there is a change in control of either party; 

	 	•	 	 either party is the subject of any actual or contemplated legal proceedings outside the ordinary course of business; and 

  

	 	•	 	 there is any adverse material change in the status of TDR. 

  

	6.	TERM, SATISFACTION AND WAIVER OF CONDITIONS PRECEDENT 

  

	 	•	 	 The Conditions Precedent contained in Clause 5 must be satisfied within a period of 15 days of the date of signing of this Terms Sheet. Failure to satisfy the
Conditions Precedent within 15 days will terminate this Terms Sheet. 

  

	 	•	 	 There will be no active solicitation by Tripos. However, Tripos will continue to pursue the currently outstanding offer by certain TDR Management to purchase the
business in parallel with the transaction contemplated in this term sheet. Tripos shall be entitled to receive and consider offers from third parties for the acquisition of TDR only after a period of 15 days has elapsed after the signing of this
Terms Sheet. 

  

	 	•	 	 There will be no change in the business or structure of Tripos during the period of the operation of this Term Sheet except for the pursuit of legitimate
opportunities to grow the business. 

  

	7.	DUE DILIGENCE 

 Tripos will assist CBI in good faith
in connection with the due diligence investigations contemplated by this Terms Sheet. 
  

	8.	CONFIDENTIALITY 

 “Confidential
Information” of a party, as that phrase is used in this Terms Sheet and in any resulting agreement based on this Terms Sheet, will mean any and all technical and non-technical information, including, but not limited to, patent, copyright, trade
secret and proprietary information, techniques, sketches, drawings, models, inventions, know-how, processes, apparatus, equipment, algorithms, software programs, source code, object code, formulas and documentation related to the current, future and
proposed products and services of such party, and includes without limitation such party’s information concerning its respective research, experimental work, development, design details and specifications, engineering, financial information,
procurement requirements, purchasing, manufacturing, customer lists, advertiser lists, business forecasts, sales, merchandising, marketing plans and other business information. “Confidential Information” also includes proprietary or
confidential information of any third party that may disclose such information to a party in the course of such party’s business. 
 The
parties hereto agree that they will not make use of, disseminate or in any way disclose Confidential Information of the other party to any person, firm or business, except as required by applicable law or to the extent necessary to fulfil the
purposes contemplated by this Terms Sheet and any definitive agreement based hereon and any purpose that the other party may hereafter authorise in writing. Each party agrees to treat all Confidential Information of the other party with the same
degree of care as they accord to their own Confidential Information, and each party warrants that it will exercise reasonable care to protect its own Confidential Information. Each party will immediately give notice to the other party of any
unauthorised use or disclosure of such 

 
party’s Confidential Information, and agrees to assist in remedying any such unauthorised use or disclosure of the other party’s Confidential
Information. 
 A party’s obligations with respect to any portion of the other party’s Confidential Information will terminate when
such party can provide evidence that (i) it was in the public domain at or subsequent to the time of its disclosure to the receiving party; (ii) it was rightfully in the receiving party’s possession free of any obligation of
confidence at or subsequent to the time of its disclosure to the receiving party; (iii) it was developed by employees or agents of the receiving party independently of and without reference to any information communicated between the parties;
or (iv) the communication was in response to a valid order by a court or other governmental body, was otherwise required by law, or was necessary to establish the rights of either party under this Terms Sheet or under any final agreement based
hereon. 
 All Confidential Information of a party will remain the property of the disclosing party and in the event of any termination of
the negotiations, all Confidential Information, including all copies thereof, will be returned to the owner of such Confidential Information. 
 The parties
agree and acknowledge that the requirement of confidentiality as set out herein will survive the termination of this transaction for a period of 10 years irrespective of whether a definitive agreement relating to the proposed Transaction is entered
into or not. 
  

	9.	COSTS 

 The parties will be responsible for their
own costs including the costs of obtaining all legal and accounting advice on this transaction. 
  

	10.	PUBLIC DISCLOSURE 

 Each party agrees that:

  

	 	•	 	 unless required by applicable law, it will not make any public announcements without first seeking the approval of the other; 

  

	 	•	 	 the wording of any announcement will be drafted jointly and all announcements will be made jointly; and 

  

	 	•	 	 unless required by applicable law, the timing of all announcements will be by mutual agreement between the parties. 

 Where a party is required by applicable law to make public disclosure of this Terms Sheet or the Transaction, such party will inform the other party of the requirement
and the parties will attempt to jointly draft the notice in good faith. 

	11.	TERMINATION 

 This Terms Sheet will terminate in the
event a definitive agreement relating to the Transaction is not executed on or before 04 May 2007. In addition, CBI may terminate this Terms Sheet at any time prior to the execution of a definitive agreement relating to the Transaction. Upon
such termination, except as noted in clause 13 hereto, CBI shall have no further obligation (financial or otherwise) to Tripos. 
  

	12.	AMENDMENT 

 Any variation to this Terms Sheet must
be in writing and executed by each party hereto. 
  

	13.	SURVIVAL OF CLAUSES 

 In the absence of a definitive
agreement relating to the Transaction being entered into between the parties on or before 04 May 2007 or in the event of termination before completion of the Transaction, only clauses 8 (Confidentiality), 9 (Costs) and 10 (Public Disclosure)
will survive the termination of this Terms Sheet. 

 Signed by the Parties 
  

					
	 SIGNED for and on behalf of
 COMMONWEALTH
 BIOTECHNOLOGIES INC
 by its duly authorised officer in
 the presence of
	 	 )
 )
 )
 )
	 	 /s/ Paul D’Sylva

		 		 	Signature
			
	 /s/ Richard J. Freer
	 		 	 Dr. Paul D’Sylva

	Signature of Witness	 		 	Full Name
		 		 	
	 Richard J. Freer, Ph.D.,
Chairman and
Chief Operating Officer
	 		 	 CEO

	Full Name of Witness	 		 	Position
			
	 SIGNED for and on behalf of
 TRIPOS INC by its
duly
 authorised officer in the
 presence of
	 	 )
 )
 )
 )
	 	 /s/ John P. McAlister

		 		 	Signature
			
	 /s/ John Yingling
	 		 	 John P. McAlister, Ph.D.

	Signature of Witness	 		 	Full Name
			
	 John Yingling
CFO, Tripos (DE)
	 		 	 President & CEO

	Full Name of Witness	 		 	Position

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]